GLP-1 Agonists Show Promising Potential for Psychiatric Disorders Beyond Metabolism

Originally developed for type 2 diabetes and obesity, GLP-1 Receptor Agonists (GLP-1 RAs) like semaglutide and liraglutide are increasingly recognized for their pleiotropic effects, including potential neurological benefits. While preclinical studies hinted at neuroprotective and mood-modulating properties, there has been a lack of a comprehensive, systematic review synthesizing the evidence for their psychiatric applications in human populations and animal models.

The review found consistent evidence for GLP-1 RAs' neuroprotective effects, with semaglutide reducing neuroinflammation markers (indicators of inflammation in the brain) by up to 35% in preclinical models of stress-induced depression. In human studies, liraglutide was associated with a 2.5-fold lower incidence of major depressive episodes in patients with type 2 diabetes compared to placebo (p<0.001), suggesting a direct mood-stabilizing effect. A meta-analysis within the review highlighted a 15% reduction in anxiety scores (measured by the Hamilton Anxiety Rating Scale, HAM-A) across 7 clinical trials using various GLP-1 RAs in obese or diabetic patients. > The most significant finding was the 43% reduction in the risk of developing new-onset depression or anxiety disorders observed in obese patients treated with GLP-1 RAs over a 2-year period compared to control groups (p<0.0001). Furthermore, exenatide showed promise in reducing symptoms of binge eating disorder, with 60% of patients achieving remission in one pilot study, compared to 20% in the placebo group.